Analysis concerning histology and the presence of anti-p53 antibodies showed that patients with adenocarcinoma had a significantly poorer survival if they expressed anti-p53 antibodies (n = 23, p = 0.01). This evidence concerns the gene TP53 and adenocarcinoma.